In one paragraphArticle in Future medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Kaito OhtaLaboratory of Pharmaceutical Manufacturing Chemistry, Kyoto Pharmaceutical University, 1 Misasagi-Shichono-cho, Yamashina-ku, Kyoto, 607-8412, Japan.
Hiromi IiLaboratory of Clinical Oncology, Kyoto Pharmaceutical University, 5 Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto, 607-8414, Japan.ORCID 0000-0003-1152-7767 Mei TakahashiLaboratory of Pharmaceutical Manufacturing Chemistry, Kyoto Pharmaceutical University, 1 Misasagi-Shichono-cho, Yamashina-ku, Kyoto, 607-8412, Japan.
Chiami MoyamaLaboratory of Clinical Oncology, Kyoto Pharmaceutical University, 5 Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto, 607-8414, Japan.
Shota AndoLaboratory of Clinical Oncology, Kyoto Pharmaceutical University, 5 Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto, 607-8414, Japan.
Masaya MoriLaboratory of Clinical Oncology, Kyoto Pharmaceutical University, 5 Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto, 607-8414, Japan.
Maho MasudaLaboratory of Clinical Oncology, Kyoto Pharmaceutical University, 5 Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto, 607-8414, Japan.
Hisanori NambuLaboratory of Pharmaceutical Manufacturing Chemistry, Kyoto Pharmaceutical University, 1 Misasagi-Shichono-cho, Yamashina-ku, Kyoto, 607-8412, Japan.ORCID 0000-0002-5186-8868 Susumu NakataLaboratory of Clinical Oncology, Kyoto Pharmaceutical University, 5 Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto, 607-8414, Japan.ORCID 0000-0002-9950-7543 Naoto KojimaLaboratory of Pharmaceutical Manufacturing Chemistry, Kyoto Pharmaceutical University, 1 Misasagi-Shichono-cho, Yamashina-ku, Kyoto, 607-8412, Japan.ORCID 0000-0002-4544-4583 Funding
Japan Society for the Promotion of Science 16K08330 and 24K09742Kyoto Pharmaceutical UniversityMinistry of Education, Culture, Sports, Science and Technology S1511024L
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic AgentsCell ProliferationEthylene GlycolLung NeoplasmsA549 CellsAmidesAnimalsDrug Screening Assays, AntitumorHeterocyclic CompoundsHumansMiceMolecular StructureStructure-Activity RelationshipAmidesAntineoplastic AgentsEthylene GlycolHeterocyclic CompoundsAMP-activated protein kinaseantitumor agentsethylene glycolmitochondrial inhibitornon-small cell lung cancer cellsoxidative phosphorylationstructure–activity relationshipsthiophene-3-carboxamide
Identifiers
PMID39297548
PMCPMC11559366
What OpenQuestion holds
Textmetadata
Read underepoch 390